Paxlovid does not increase risk of COVID reinfection: study

Published Date: 16 Feb 2023

Although there are concerns that the use of Paxlovid increases the risk of COVID-19 returning, the results are clear.

Read Full News

Latest News

Q3 2026 Preview: 4 FDA Decisions to Watch

Q3 2026 Preview: 4 FDA Decisions to Watch

FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older

FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older

GLP-1s Are Treating a Diagnosis. Who’s Treating the Patient?

Without nutrition and eating disorder support, clinicians prescribing GLP-1s may miss undernutrition, muscle loss, and harmful restriction.

High-Dose Probiotic Helps Patients With Chronic Diarrhea

A high-dose eight-strain probiotic is linked to a decrease in the percentage of fecal primary bile acids among patients with bile acid malabsorption.

3 Common Drugs Older Adults Might Be Overusing

Recent studies of three medications or classes of drugs widely used among older Americans illustrate the problem.

Standing Up More May Not Cut Risk for Cancer Death

Only replacing sitting with physical activity seems to help.

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

Q3 2026 Preview: 4 FDA Decisions to Watch

FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older

Without nutrition and eating disorder support, clinicians prescribing GLP-1s may miss undernutrition, muscle loss, and harmful restriction.

A high-dose eight-strain probiotic is linked to a decrease in the percentage of fecal primary bile acids among patients with bile acid malabsorption.

Recent studies of three medications or classes of drugs widely used among older Americans illustrate the problem.

Only replacing sitting with physical activity seems to help.

News All Time

Reducing Infusion Wait Times at VA New Jersey

VA New Jersey slashed chemo infusion wait times 32% — from 164 to 106 minutes — through order templates, pre-visit bloodwork, and a fast-track room.

Evaluating the Implementation of 60-Minute Iron Infusions

Safe 60-minute iron dextran infusion protocol has been demonstrated at large institutions, but its impact on patient safety at small, rural clinics has not been reported.

Hospital Outcomes Associated With SUDs in Pancreatic Cancer

This project sought to evaluate the impact of substance use disorders on inpatient outcomes among hospitalized patients with pancreatic cancer.

Expanding CoC Standard 5.9

Smoking cessation improves treatment response and survival, while reducing recurrence and complications in cancer patients.

Cannabis Edibles Impair Driving Even Below Legal THC Limits

Cannabis edibles dose-dependently impair simulated driving performance hours after ingestion at THC blood concentrations below roadside enforcement levels.

Pollutant Exposure Tied to Increased Suicide Risk

Air pollutant exposure, especially to PM2.5, PM10, and nitrogen dioxide, is associated with increased risk for death by suicide, attempted suicide, and suicidal ideation.

Does Sex Factor in the Obstetrical Dilemma?

Baby boys tend to be larger at birth than girls. New research asks whether those differences may help explain more challenging deliveries.

SLE Linked to Increased Risk for Stroke

Patients with systemic lupus erythematosus face a substantially elevated risk for ischemic and hemorrhagic stroke compared with control individuals, a meta-analysis shows.

Shingles Vaccine Boosts Antibodies in People Living With HIV

A recombinant zoster vaccine builds strong antibody protection in people living with HIV, regardless of their CD4 count — but their cellular immune response still lags behind those without HIV.

Remote Videos Can Reliably Flag Cerebral Palsy Risk

Remote video-based assessment at 3-4 months of corrected age can reliably flag the risk for cerebral palsy in infants born very preterm.

Primary Care Quality Tied to Hospital Use in Multimorbidity

In patients with multimorbidity, better primary care checks increase the odds of outpatient and emergency care, but multimorbidity-specific checks lower the odds of elective hospital admissions.

AI in Gastroenterology: Benefits vs Harms

AI applications are poised to become the mandated standard of practice in gastroenterology, and in some institutions already are.

Esophagitis Dissecans Superficialis in Woman With Dysphagia

A woman presents with progressive dysphagia and vomiting; endoscopy reveals extensive esophageal mucosal sloughing consistent with esophagitis dissecans superficialis.

Laughter Really Is The Best Medicine

The data on laughter are more serious than you’d expect. Dr Neil Skolnik breaks down the physiological benefits of humor.

AI in Medicine Reduces Burden, Not Judgment

AI in medicine isn’t about replacing clinical reasoning. It’s about freeing up physicians to do more of what only they can do.

Gaps in Access to Maternity Care Tied to Labor Induction

Maternal residence in rural, lower-access counties is associated with an increased risk for labor induction at full term.

Recommended News For You

Stem Cell Transplant Associated With Better PFS in NKTCL

In inflammatory breast cancer, ER beta regulates estrogen signaling.

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

Risk of a second cancer after early breast cancer is low, say new findings

Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.

The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.

Breast cancer: Why it's difficult to treat and what new approaches are on the horizon

Recommended Articles For You

The Rise of Immunotherapy: New Advances in Cancer Treatment 

Unmasking the Subtle Symptoms of Colon Cancer 

Finding Support: Connecting with the Vitiligo Community 

Guidance for Managing Complex Anticoagulation 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.

2.

In 18 States, alcohol exclusion laws are still in effect.

3.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

4.

Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer

5.

Early breast cancer detection may be possible with a wearable ultrasound scanner.

1.

The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease 

2.

A Closer Look at MCV Modules: Features, Functions, and Benefits 

3.

Clonal Evolution Genomics in Dynamic Tumor Ecosystems

4.

Intratumoral Drug Distribution in Solid Tumors

5.

CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

3.

Efficient Management of First line ALK-rearranged NSCLC

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot